Showing 2121-2130 of 5697 results for "".
- Novartis Announces Positive Phase 3 Results for Ianalumab in Sjögren’s Diseasehttps://modernod.com/news/novartis-announces-positive-phase-3-results-for-ianalumab-in-sjogrens-disease/2484297/Novartis announced new late-breaking data from the NEPTUNUS-1 and NEPTUNUS-2 phase 3 trials evaluating ianalumab in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. The results, presented during the American College of Rheumatol
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- NEJM Publishes Study Demonstrating Vision Restoration with Brain-Computer Interface Retinal Implanthttps://modernod.com/news/nejm-publishes-study-demonstrating-vision-restoration-with-brain-computer-interface-retinal-implant/2484211/The New England Journal of Medicine (NEJM) published results from a clinical trial demonstrating that Science Corporation’s PRIMA brain-computer interface (BCI) retinal implant can restore functional
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- Topcon Healthcare Signs Definitive Agreement to Acquire Toku Inc.https://modernod.com/news/topcon-healthcare-signs-definitive-agreement-to-acquire-toku-inc/2484189/Topcon Healthcare announced it has signed a definitive agreement to acquire Toku, Inc., a San Diego-based artificial intelligence (AI) health technology company. Financial terms of the deal were not disclosed.
- Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatmenthttps://modernod.com/news/avisi-technologies-receives-fda-approval-to-study-novel-approach-to-glaucoma-treatment/2484182/Avisi Technologies announced that the FDA has approved an investigational device exemption (IDE) for its glaucoma treatment device, VisiPlate. This milestone paves the way for the company’s SAPPHIRE clinical trial, which will evaluate the device in patie
- OcuSciences Secures CE Mark for OcuMet Beacon, Expands European Deploymenthttps://modernod.com/news/ocusciences-secures-eu-ce-clearance-for-ocumet-beacon-expands-european-deployment/2484181/OcuSciences has received CE Mark clearance for its OcuMet Beacon, a diagnostic instrument designed to enhance clinicians’ ability to assess eye health and detect retinal disorders. The CE mark signifies that the OcuMet Beacon meets the health, safet
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- Lovell and DefEYE Partner to Expand Access to Biovance Ocular Biologics Across Federal Healthcare Systemshttps://modernod.com/news/lovell-government-services-and-defeye-partner-to-expand-access-to-biovance-ocular-biologics-across-federal-healthcare-systems/2484164/Lovell Government Services and DefEYE, the provider of Biovance decellularized basement membranes for ocular use, announced a partnership to serve federal healthcare systems, including the Veterans Health Administration, the Department of Defense Military
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration